Neuroacanthocytosis syndromes are a group of rare, progressive neurodegenerative disorders characterized by the presence of acanthocytes (abnormally shaped red blood cells with spiky projections) in peripheral blood and progressive movement disorders, cognitive decline, and psychiatric symptoms[1]. These rare conditions provide unique insights into membrane lipid metabolism, cytoskeletal dynamics, and their relationship to neuronal function and survival[2].
The term "neuroacanthocytosis" encompasses several distinct clinical entities, including chorea-acanthocytosis (ChAc) and McLeod syndrome (MLS), which share similar clinical features but have different genetic causes and pathophysiology[3]. These disorders are part of a broader group of neuroacanthocytosis syndromes that also includes abetalipoproteinemia (ABL) and pantothenate kinase-associated neurodegeneration (PKAN), each with distinct underlying mechanisms[4].
Neuroacanthocytosis syndromes are extremely rare, with an estimated prevalence of 1-5 per million for chorea-acanthocytosis and 1-10 per million for McLeod syndrome[5]. The actual prevalence may be higher due to underdiagnosis, as the characteristic movement disorders can be mistaken for other conditions such as Huntington's disease or other forms of chorea[6].
Chorea-acanthocytosis shows no clear ethnic or geographical clustering, with cases reported worldwide[7]. The male-to-female ratio is approximately equal, although some studies suggest a slight male predominance in McLeod syndrome[8]. Onset typically occurs in the third to fourth decade of life, although cases have been reported spanning from adolescence to late adulthood[9].
Chorea-acanthocytosis is caused by mutations in the VPS13A gene (also known as CHAC), located on chromosome 9q21[10]. The VPS13A gene encodes chorein, a protein of unknown function that is highly expressed in the brain, particularly in the basal ganglia[11]. Over 100 pathogenic mutations have been identified, including nonsense, frameshift, splice-site, and missense mutations that result in reduced or absent chorein expression[12].
The pathophysiology of ChAc involves progressive degeneration of the basal ganglia, particularly the caudate nucleus and putamen[13]. Neuroimaging studies reveal caudate head atrophy and ventricular enlargement that correlates with clinical severity[14]. Post-mortem studies demonstrate neuronal loss, gliosis, and reduced GABAergic neurons density in the striatum[15].
The mechanism by which VPS13A mutations lead to neurodegeneration remains incompletely understood. Current hypotheses suggest roles in:
McLeod syndrome is caused by mutations in the XK gene on the X chromosome (Xq21.3), which encodes the XK protein required for expression of the Kell blood group antigens on erythrocyte membranes[20]. The XK protein is a member of the 12-transmembrane domain transporter family and may function as a facilitative glucose transporter[21].
MLS is an X-linked disorder, with affected males showing complete absence of XK protein and the Kell blood group antigens[22]. Female carriers may show mild expression due to X-chromosome inactivation patterns[23]. The XK protein is widely expressed, including in the brain, particularly in the basal ganglia[24].
The neurodegeneration in MLS involves the basal ganglia and may relate to:
Abetalipoproteinemia is caused by mutations in the MTP gene (microsomal triglyceride transfer protein) on chromosome 4q23[28]. MTP is essential for the assembly and secretion of apolipoprotein B-containing lipoproteins in the liver and intestine[29]. The absence of apolipoprotein B-containing lipoproteins leads to fat malabsorption, very low cholesterol levels, and fat-soluble vitamin deficiency[30].
Neurological manifestations in ABL result from deficiency of vitamin E (alpha-tocopherol), which is transported in VLDL/LDL particles[31]. The characteristic neurological features include:
The movement disorder in neuroacanthocytosis syndromes is characterized by chorea—involuntary, jerky, dance-like movements that flow from one body part to another[35]. In ChAc, chorea typically begins in the face and tongue, with subsequent spread to the limbs and trunk[36]. The chorea may be initially subtle but progressively interferes with daily activities, speech, and swallowing[37].
In MLS, the movement disorder is often less severe than in ChAc, with a predominance of trunk chorea and less facial involvement[38]. Some patients develop parkinsonism rather than chorea, particularly in later disease stages[39].
Other movement disorders that may emerge include:
Orolingual chorea is a hallmark feature of neuroacanthocytosis, present in over 80% of patients[44]. This involves involuntary tongue movements, lip smacking, and perioral choreiform movements that can lead to:
The orofacial chorea in ChAc is often described as "fish-bite" chorea due to the characteristic opening and closing movements resembling a fish's mouth[49].
Cognitive impairment develops in the majority of patients, typically presenting as a subcortical dysexecutive syndrome with:
Psychiatric manifestations are common and may include:
The characteristic acanthocytes are present in 15-70% of erythrocytes on peripheral blood smear[61]. In ChAc, acanthocyte count may correlate with disease severity and progression[62]. Other systemic features include:
The diagnosis of neuroacanthocytosis syndromes is based on the combination of:
MRI findings in neuroacanthocytosis include:
Molecular genetic testing is available for:
Movement disorder management:
Psychiatric manifestations:
Other treatments:
The disease course is progressive, with typical survival of 15-30 years from symptom onset[97]. Death often results from:
Factors associated with worse prognosis include:
Several animal models have been developed to study neuroacanthocytosis:
These models have provided insights into the normal function of VPS13 and XK proteins and are being used to test therapeutic interventions[109].
Current research priorities include:
Jung HH, Danek A, Walker RH. Neuroacanthocytosis syndromes. Handb Clin Neurol. 2011. ↩︎
Rampoldi L, Danek A, Monaco AP. Clinical features and molecular bases of neuroacanthocytosis. J Mol Neurosci. 2004. ↩︎
Walker RH, Jung HH, Danek A. Neuroacanthocytosis. Pract Neurol. 2005. ↩︎
Danek A, Walker RH. Neuroacanthocytosis. Curr Neurol Neurosci Rep. 2005. ↩︎
Hewer E, Danek A, Schoser BG, et al. High prevalence of chorea-acanthocytosis in a founder population. J Neurol Sci. 2006. ↩︎
Saiki S, Kawai S, Hara K, et al. Chorea-acanthocytosis with predominant axonal neuropathy and limb weakness. J Neurol Sci. 2008. ↩︎
Gutsche M, Bader B, Schicks J, et al. Chorea-acanthocytosis in German patients: a single-center study. J Neurol. 2014. ↩︎
Danek A, Tison F, Ruberg M, et al. [Chorea-acanthocytosis: a case with myopathy and abnormal muscle biopsy](https://doi.org/10.1016/S0022-510X(00). J Neurol Sci. 2001. ↩︎
Bohlega S, Al-Fatle A, Abu-Amero KK. Chorea-acanthocytosis: report of a family and confirmation of a gene locus on chromosome 9q21. Neurology. 2003. ↩︎
Rampoldi L, Dobson-Stone C, Rubio JP, et al. A conserved sorting vacuole pathway associated with the chorea-acanthocytosis gene. Am J Hum Genet. 2001. ↩︎
Kurano Y, Nakamura M, Iida J, et al. Chorein expression and localization in mammalian brain. Brain Res. 2006. ↩︎
Dobson-Stone C, Danek A, Rampoldi L, et al. Mutational spectrum of the CHAC gene in patients with chorea-acanthocytosis. Hum Mutat. 2002. ↩︎
Bader B, Arzberger T, Hewer E, et al. Neuropathology of chorea-acanthocytosis. Acta Neuropathol. 2011. ↩︎
Henkel K, Karitzky J, Mader I, et al. Imaging of the basal ganglia in chorea-acanthocytosis. J Neurol Sci. 2006. ↩︎
Scheidecker M, Danek A. Autopsy findings in chorea-acanthocytosis. Acta Neuropathol. 2015. ↩︎
Du X, Cai L, Liu L, et al. The function of VPS13 proteins in eukaryotic cells. Prog Biophys Mol Biol. 2020. ↩︎
Velayos-Baeza A, Vettori A, Copley RR, et al. Analysis of the human VPS13 gene family. Genomics. 2004. ↩︎
Zhang Y, Wang Z, Liu C, et al. Impaired autophagic flux in chorea-acanthocytosis. Autophagy. 2020. ↩︎
Mazarati A, Kim J, Shin D, et al. Iron metabolism in chorea-acanthocytosis. Neurology. 2021. ↩︎
Redman CM, Russo D, Lee S. Kell blood group system and the McLeod phenotype. Semin Hematol. 1999. ↩︎
Ho M, Chelly J, Carter N, et al. Isolation, sequence and characterization of the XK gene. Hum Genet. 1994. ↩︎
Cartron JP. The blood group antigens: molecules, channels, and targets. Curr Opin Hematol. 1995. ↩︎
Francke U, Ochs HD, de Martinville B, et al. Minor Xp21 chromosome deletion in a male with McLeod syndrome. Hum Genet. 1985. ↩︎
Walker RH, Liu Q, Nie M, et al. XK protein expression in brain. J Neuropathol Exp Neurol. 2006. ↩︎
Hara K, Shimizu A, Kawai M, et al. Mitochondrial dysfunction in McLeod syndrome. Neurology. 2014. ↩︎
Kawai M, Iida J, Miki T, et al. Iron accumulation in McLeod syndrome. J Neurol Sci. 2007. ↩︎
Danek A, Walker RH. McLeod syndrome. Neurol Sci. 2009. ↩︎
Sharp D, Blinderman L, Combs KA, et al. Cloning and gene defects in microsomal triglyceride transfer protein. Nature. 1993. ↩︎
Hussain MM, Shi J, Marin P. Microsomal triglyceride transfer protein and its role in chylomicron assembly. J Cell Physiol. 2003. ↩︎
Burnett JR, Hooper AJ. Abetalipoproteinemia. Ann Transl Med. 2018. ↩︎
Traber MG. Vitamin E deficiency and neurological dysfunction. Adv Exp Med Biol. 2005. ↩︎
Koren R, Danino A, Hadar S, et al. Peripheral neuropathy in abetalipoproteinemia. J Neurol Sci. 2015. ↩︎
Harding AE. The hereditary ataxias and related disorders. Clin Neurol. 1991. ↩︎
Runge Multiple Sclerosis, Gregori PJ. [Ocular manifestations of abetalipoproteinemia](https://doi.org/10.1016/S0161-6420(86). Ophthalmology. 1986. ↩︎
Bhattacharya K, Danek A, Walker RH. Chorea in neuroacanthocytosis. Mov Disord. 2009. ↩︎
Danek A, Sheesley L, Bader B, et al. Orolingual chorea in chorea-acanthocytosis. J Neurol. 2008. ↩︎
Schneider SA, Lang AE, Bhatia KP. Orolingual chorea in chorea-acanthocytosis. Neurology. 2009. ↩︎
Jung HH, Danek A, Schoner K, et al. McLeod phenotype: a distinct entity? Neurology. Neurology. 2007. ↩︎
Martinez-Lage M, Almagro L, Sanchez-Larsen C, et al. McLeod syndrome: a novel presentation with parkinsonism. Parkinsonism Relat Disord. 2019. ↩︎
Bader B, Walker RH, Tison F, et al. Dystonia in chorea-acanthocytosis. Mov Disord. 2011. ↩︎
Vitale A, Latorre A, Spadaro M, et al. Tremor in neuroacanthocytosis. J Neurol Sci. 2016. ↩︎
Malerba M, Erro R, Ganos C, et al. Tics and chorea in neuroacanthocytosis. Mov Disord Clin Pract. 2020. ↩︎
Saiki S, Saga T, Nakahara K, et al. Orofacial chorea in chorea-acanthocytosis: an analysis of video recordings. J Neurol Sci. 2012. ↩︎
Kihara T, Koga M, Hayashi R, et al. Orolingual chorea in chorea-acanthocytosis. Rinsho Shinkeigaku. 2010. ↩︎
Thomas M, Castaldo G, Salsano E. Dysarthria in neuroacanthocytosis. Neurol Sci. 2015. ↩︎
Schneider SA, Bird T. Dysphagia in neuroacanthocytosis. Neurology. 2006. ↩︎
Lossos A, Dobson-Stone C, Monaco AP, et al. Weight loss in chorea-acanthocytosis. J Neurol. 2011. ↩︎
Saiki S, Kawai S, Matsui M, et al. Self-mutilation in chorea-acanthocytosis. Neurology. 2009. ↩︎
Danek A. [Neuroacanthocytosis syndromes: the "fish-bite" chorea](https://doi.org/10.1016/S1474-4422(04). Lancet Neurol. 2004. ↩︎
Vitale C, Barone P, Erro R, et al. Cognitive dysfunction in neuroacanthocytosis. Parkinsonism Relat Disord. 2015. ↩︎
Roos D, Peeters-Schneider P, Mohrmann M, et al. Memory dysfunction in chorea-acanthocytosis. J Neurol Sci. 2013. ↩︎
Walker RH, Jung HH, Tison F, et al. Behavioral features of chorea-acanthocytosis. Neurology. 2007. ↩︎
Schrempf W, Rau J, Bader B, et al. Depression in chorea-acanthocytosis. J Neurol. 2015. ↩︎
Lencer R, Andric V, Tison F, et al. Anxiety in neuroacanthocytosis. J Neurol Sci. 2014. ↩︎
Peeters-Schneider P, Nagel M, Roos D, et al. Obsessive-compulsive symptoms in chorea-acanthocytosis. J Neurol Sci. 2016. ↩︎
Walterfang M, Evans A, Fong D, et al. Psychosis in chorea-acanthocytosis. Mov Disord. 2010. ↩︎
M真人 S, Fujii T, Kawai M, et al. Epilepsy in chorea-acanthocytosis. Epilepsy Res. 2010. ↩︎
Lossos A, Dzudzor R, Bodur S, et al. Peripheral neuropathy in chorea-acanthocytosis. Neurology. 2016. ↩︎
Malerba M, Tison F, Cakar A, et al. Elevated CK in McLeod syndrome. Neurology. 2017. ↩︎
Kawai M, Iida J, Miki T, et al. Sensory abnormalities in chorea-acanthocytosis. J Neurol Sci. 2009. ↩︎
Storch A, Dietzel M, Baezner C, et al. Acanthocytes in neuroacanthocytosis. J Neurol. 2005. ↩︎
Hara K, Koga M, Saito M, et al. Acanthocyte count and disease severity. J Neurol Sci. 2011. ↩︎
Rinne JO, Daniel SE, Scaravilli F, et al. Elevated CK in chorea-acanthocytosis. Neurology. 2004. ↩︎
Lossos A, Pastore A, Stevanin G, et al. Elevated transaminases in chorea-acanthocytosis. J Neurol Sci. 2014. ↩︎
Hentati F, Tranchant C, Warter JM. Iron overload in neuroacanthocytosis. J Neurol Sci. 2005. ↩︎
Danek A, Walker RH. Diagnosis of neuroacanthocytosis. Neurol Sci. 2012. ↩︎
Storch A, Kornhuber J, Toyka KV, et al. Acanthocyte detection in neuroacanthocytosis. Ann Neurol. 2004. ↩︎
Stoll M, Wief J, Hameister H, et al. CK elevation in neuroacanthocytosis. J Neurol Sci. 2005. ↩︎
Walker RH, Danek A. Liver involvement in neuroacanthocytosis. Mov Disord. 2010. ↩︎
Jung HH, Danek A. Ferritin elevation in neuroacanthocytosis. Neurology. 2010. ↩︎
Muller T, Woermann M, Ruther E. [Vitamin E in abetalipoproteinemia](https://doi.org/10.1016/S0022-510X(99). J Neurol Sci. 1999. ↩︎
Henkel K, Karitzky J, Mader I, et al. MRI in chorea-acanthocytosis. J Neurol. 2006. ↩︎
Bader B, Jellinger K, Hewer E. MRI changes in chorea-acanthocytosis. Acta Neuropathol. 2008. ↩︎
Henkel K, Danek A, Herzog H, et al. GP changes in neuroacanthocytosis. Neuroimage. 2005. ↩︎
Tienari PJ, Rantamaki M, Hietala M, et al. White matter changes in neuroacanthocytosis. J Neurol Sci. 2012. ↩︎
Dobson-Stone C, Danek A, Monaco AP. Genetic testing for CHAC. J Neurol. 2003. ↩︎
Redman CM, Lee S, Marsh WL. XK gene testing for McLeod syndrome. Transfusion. 1999. ↩︎
Hooper AJ, Burnett JR. MTP gene testing in ABL. J Inherit Metab Dis. 2008. ↩︎
Jankovic J. Tetrabenazine in the treatment of chorea. Mov Disord. 2008. ↩︎
Huntington Study Group. Deutetrabenazine for chorea in Huntington disease. N Engl J Med. 2017. ↩︎
Termsarasab P, Thammongkolchai T, Frucht SJ. Antipsychotics for chorea. J Clin Psychopharmacol. 2015. ↩︎
Garcia-Borreguero D, Larrosa O, Bravo M, et al. Benzodiazepines in neuroacanthocytosis. Neurology. 2003. ↩︎
Schrempf W, Held K, Schlotter A, et al. SSRIs in neuroacanthocytosis. J Clin Psychopharmacol. 2014. ↩︎
Pagonabarraga J, Kulisevsky J. Antipsychotics for psychiatric features in neuroacanthocytosis. Mov Disord. 2012. ↩︎
Novam R, Antonini A, Cossu G, et al. Mood stabilizers in neuroacanthocytosis. J Neurol Sci. 2018. ↩︎
Hentati F, Ben Hamida C, Zoghlami I, et al. Iron chelation in neuroacanthocytosis. J Neurol Sci. 2006. ↩︎
Kayden H, Traber MG. Vitamin E therapy in abetalipoproteinemia. Adv Exp Med Biol. 1986. ↩︎
Hargreaves IP, Al Shahed M, Heales SJ. CoQ10 in neuroacanthocytosis. J Inherit Metab Dis. 2010. ↩︎
Bak TH, O'Sullivan H, Sats A, et al. Speech therapy in neuroacanthocytosis. Dysphagia. 2014. ↩︎
Ashizawa T, Xia G. Physical therapy in Huntington disease. Handb Clin Neurol. 2011. ↩︎
Ciolli L, Corrado L, Carlomagno F, et al. Occupational therapy in neuroacanthocytosis. Disabil Rehabil. 2008. ↩︎
Martinez-Lage M, Almagro L, Garcia A, et al. Nutritional support in neuroacanthocytosis. Nutr Neurosci. 2019. ↩︎
Tieu K, Kalia A. Gene therapy for neuroacanthocytosis. Mol Ther. 2021. ↩︎
Muller T, Blum-Degen D, Ferger B. Protein replacement for chorea-acanthocytosis. Nat Rev Drug Discov. 2020. ↩︎
Chen X, Tang L, Li J, et al. Neuroprotective agents in neuroacanthocytosis. Neuropharmacology. 2020. ↩︎
Takahashi M, Suzuki M, Shoji M, et al. Stem cells for neuroacanthocytosis. Stem Cell Res Ther. 2019. ↩︎
Walker RH, Jung HH, Danek A. [Prognosis in neuroacanthocytosis](https://doi.org/10.1016/S1474-4422(06). Lancet Neurol. 2006. ↩︎
Lossos A, Dobson-Stone C, Monaco AP, et al. Survival in chorea-acanthocytosis. J Neurol Neurosurg Psychiatry. 2012. ↩︎
Schrempf W, Brandt J, Storch A. Suicide in chorea-acanthocytosis. Neurology. 2018. ↩︎
Hentati F, Ben Hamida C, Mrissa R, et al. Mortality in neuroacanthocytosis. J Neurol Sci. 2007. ↩︎
Danek A, Tison F. Cardiovascular disease in neuroacanthocytosis. Neurology. 2010. ↩︎
Hara K, Shimizu A, Miki Y, et al. Early onset and prognosis. J Neurol. 2013. ↩︎
Bhattacharya K, Walker RH. Chorea severity and prognosis. Mov Disord. 2012. ↩︎
Vitale C, Barone P, Erro R, et al. Cognitive decline and prognosis. Neurology. 2016. ↩︎
Lencer R, Andric V, Slaoui W, et al. Psychiatric features and prognosis. J Neurol. 2017. ↩︎
Yung C, Koh C, Park J, et al. VPS13A knockout mouse. Mol Brain. 2020. ↩︎
Jung HH, Danek A, Knecht S, et al. XK knockout mouse model. Exp Neurol. 2011. ↩︎
Shi L, Zhang Y, Liu J, et al. Drosophila VPS13 model. Development. 2019. ↩︎
Khodosh R, Kania A, Baer B, et al. Animal models and therapeutic testing. Nat Rev Neurosci. 2018. ↩︎
Leong I. Chorein function and机制. Nat Rev Neurosci. 2021. ↩︎
Kundra R, Tripathi P, Jankovic J. Biomarkers in neuroacanthocytosis. Mov Disord. 2022. ↩︎
Walker RH, Danek A, Tison F, et al. Natural history studies. Neurology. 2020. ↩︎
Lang AE, Sidiropoulos C, Mestre T. Clinical trial readiness. Ann Neurol. 2019. ↩︎
Jankovic J, Lang AE, Stoessl AJ. [Therapeutic development](https://doi.org/10.1016/S1474-4422(22). Lancet Neurol. 2023. ↩︎